AUSTIN, Texas--(BUSINESS WIRE)--Babson Diagnostics, a science-first medical technology company, today announced the appointments of Kristie Stanton as vice president of marketing and Vicente Armendariz as vice president of strategy, effective immediately. Stanton and Armendariz will report to Chief Executive Officer David Stein, Ph.D., and will help drive the commercialization and growth of Babson’s novel technologies that will transform the entire diagnostic blood testing process.
“I am thrilled to have Kristie and Vicente join Babson Diagnostics,” Stein said. “Their deep retail expertise and knowledge of the payor and provider landscape, coupled with Babson’s world-class technology and key strategic partnerships, will position us perfectly to achieve our ambitious vision of disrupting conventional diagnostic blood testing.”
Stanton is an accomplished and creative senior marketer with a track record of launching successful healthcare brands in retail settings. She spent more than 10 years at CVS Health, most notably leading the marketing department for MinuteClinic, the country’s largest retail medical clinic. She served as a member of the MinuteClinic executive leadership team, growing the offering to more than 1,000 clinics nationally and making the brand synonymous with retail care. More recently, she was executive director of strategic marketing and digital engagement at Aetna, a CVS Health company, where she led teams responsible for membership, new business, and digital adoption growth. She has a bachelor’s degree in marketing from Bentley University and graduated from the University of Chicago Booth School of Business Executive Education Program.
Armendariz brings a wealth of experience in corporate strategy and business development in health insurance, pharmacy services, and healthcare technology. Most recently, he was vice president of corporate strategy at HMS, a leading provider of payment accuracy and population health management solutions. He was responsible for the development of the company’s strategic plan and led all M&A, market intelligence and competitive intelligence initiatives. Previously, Armendariz worked on internal consulting, corporate strategy, and business development at notable healthcare services organizations including WellCare, CVS Health, and Humana. He has an MBA from the Thunderbird School of Global Management and graduated from Brigham Young University.
These new hires come on the heels of Babson raising $31 million in a Series B round to boost ongoing testing and development of the company’s technological ecosystem that unites innovations in collection, sample handling, and analysis. The proprietary system enables a full range of diagnostic testing using only small capillary samples taken from a finger. In these newly created leadership roles, Stanton and Armendariz will bring Babson’s platform to retail pharmacies and other convenient locations, making routine blood testing easier, more accessible, and less invasive.
About Babson Diagnostics
Babson is a science-first medical technology company focused on moving laboratory testing to the pharmacy counter to make it more accessible, convenient, and affordable. Babson has developed a model for diagnostic blood testing that maintains a high standard of accuracy yet requires only one-tenth the sample size of traditional venipuncture methods. Prior to commercialization, Babson is working with retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication. For more information, please visit www.babsondx.com.
